ConductScience.org, home
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
API referenceFor AI assistants

Trial · NCT04236141

Results by group76

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 76

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants With Complete Response (CR) at the End of Treatment (EOT) Assessment Based on Positron Emission Tomography-Computed Tomography (PET-CT) Assessed by Independent Review Committee (IRC)
Polatuzumab Vedotin Plus Bendamustine and Rituximab25.095% Confidence Interval 10.69 to 44.87percentage of participants
Percentage of Participants With Complete Response (CR) at the End of Treatment (EOT) Assessment Based on Positron Emission Tomography-Computed Tomography (PET-CT) Assessed by Independent Review Committee (IRC)
Placebo Plus Bendamustine and Rituximab14.395% Confidence Interval 1.78 to 42.81percentage of participants
Percentage of Participants With CR at the EOT Assessment Based on PET-CT as Assessed by InvestigatorPolatuzumab Vedotin Plus Bendamustine and Rituximab21.495% Confidence Interval 8.30 to 40.95percentage of participants
Percentage of Participants With CR at the EOT Assessment Based on PET-CT as Assessed by InvestigatorPlacebo Plus Bendamustine and Rituximab14.395% Confidence Interval 1.78 to 42.81percentage of participants
Percentage of Participants With Objective Response (OR) at EOT Based on PET-CT as Assessed by InvestigatorPolatuzumab Vedotin Plus Bendamustine and Rituximab28.695% Confidence Interval 13.22 to 48.67percentage of participants
Percentage of Participants With Objective Response (OR) at EOT Based on PET-CT as Assessed by InvestigatorPlacebo Plus Bendamustine and Rituximab14.395% Confidence Interval 1.78 to 42.81percentage of participants
Percentage of Participants With OR at EOT Based on PET-CT as Assessed by IRCPolatuzumab Vedotin Plus Bendamustine and Rituximab35.795% Confidence Interval 18.64 to 55.93percentage of participants
Percentage of Participants With OR at EOT Based on PET-CT as Assessed by IRCPlacebo Plus Bendamustine and Rituximab14.395% Confidence Interval 1.78 to 42.81percentage of participants
Percentage of Participants With CR at EOT Based on Computed Tomography (CT) as Assessed by InvestigatorPolatuzumab Vedotin Plus Bendamustine and Rituximab17.995% Confidence Interval 6.06 to 36.89percentage of participants
Percentage of Participants With CR at EOT Based on Computed Tomography (CT) as Assessed by InvestigatorPlacebo Plus Bendamustine and Rituximab095% Confidence Interval 0.00 to 23.16percentage of participants
Percentage of Participants With CR at EOT Based on CT as Assessed by IRCPolatuzumab Vedotin Plus Bendamustine and Rituximab17.995% Confidence Interval 6.06 to 36.89percentage of participants
Percentage of Participants With CR at EOT Based on CT as Assessed by IRCPlacebo Plus Bendamustine and Rituximab095% Confidence Interval 0.00 to 23.16percentage of participants
Percentage of Participants With OR at EOT Assessment Based on CT as Assessed by InvestigatorPolatuzumab Vedotin Plus Bendamustine and Rituximab32.195% Confidence Interval 15.88 to 52.35percentage of participants
Percentage of Participants With OR at EOT Assessment Based on CT as Assessed by InvestigatorPlacebo Plus Bendamustine and Rituximab14.395% Confidence Interval 1.78 to 42.81percentage of participants
Percentage of Participants With OR at EOT Assessment Based on CT as Assessed by IRCPolatuzumab Vedotin Plus Bendamustine and Rituximab28.695% Confidence Interval 13.22 to 48.67percentage of participants
Percentage of Participants With OR at EOT Assessment Based on CT as Assessed by IRCPlacebo Plus Bendamustine and Rituximab14.395% Confidence Interval 1.78 to 42.81percentage of participants
Percentage of Participants With Best Overall Response (BOR) Based on PET-CT or CT Only as Assessed by InvestigatorPolatuzumab Vedotin Plus Bendamustine and Rituximab53.695% Confidence Interval 33.87 to 72.49percentage of participants
Percentage of Participants With Best Overall Response (BOR) Based on PET-CT or CT Only as Assessed by InvestigatorPlacebo Plus Bendamustine and Rituximab28.695% Confidence Interval 8.39 to 58.10percentage of participants
Percentage of Participants With Best Overall Response (BOR) Based on PET-CT or CT Only as Assessed by IRCPolatuzumab Vedotin Plus Bendamustine and Rituximab53.695% Confidence Interval 33.87 to 72.49percentage of participants
Percentage of Participants With Best Overall Response (BOR) Based on PET-CT or CT Only as Assessed by IRCPlacebo Plus Bendamustine and Rituximab50.095% Confidence Interval 23.04 to 76.96percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04236141/results

API referenceFor AI assistants